Trial Profile
A phase 2, randomized, double-blind, placebo-controlled, multicenter study to confirm dose responsiveness following 12 weeks of the administration of CP-690,550 (4 doses) or placebo in subjects with active rheumatoid arthritis inadequately controlled with methotrexate alone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 16 Jun 2018 Results of pooled data from 4 Phase 2 trials (NCT00413660; NCT00550446; NCT00603512; NCT00687193) and 5 Phase 3 randomised, double-blind, placebo-controlled trials (ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307]; ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]; ORAL Step [NCT00960440]), were presented at the 19th Annual Congress of the European League Against Rheumatism.
- 08 Nov 2017 Results (n=2673) of post-hoc analysis assessing the impact of inflammation severity at baseline on efficacy and safety of tofacitinib using pooled data from four phase II trials (NCT00413660, NCT00550446, NCT00603512, NCT00687193) and five phase III trials (ORAL Scan, ORAL Solo, ORAL Sync, ORAL Standard, ORAL Step), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 17 Jun 2017 Results of a post hoc analysis from pooled data of this, another Phase II study (NCT00687193), one Phase III study (ORAL Scan; NCT00847613) and an open-label, LTE study (NCT00661661) presented at the 18th Annual Congress of the European League Against Rheumatism